Results 91 to 100 of about 3,893,535 (160)

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review

Pharmaceuticals
This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs).
Paul M. D. Gape, Michael K. Schultz, Graeme J. Stasiuk, Samantha Y. A. Terry   +3 more
doaj   +1 more source

Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues [PDF]

, 2009
This thesis focuses on peptide receptor-targeted therapies, with particular reference to the somatostatin ligand-receptor system and to radiolabelled somatostatin analogues in neuroendocrine tumours.
Bodei, Lisa, Bodei, Lisa,
core   +15 more sources

Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors

Rationale: Evaluating the long-term safety and efficacy of peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumors (mNETs) who have undergone prior bland hepatic transarterial embolization (TAE).
Adam Alayli, Ghassan El-Haddad, Jonathan R. Strosberg, Altan Ahmed, Hoang Ngo, Taymeyah E. Al-Toubah, Bela Kis, Elias Salloum, Mintallah Haider, Dhiraj Sikaria   +9 more
core   +1 more source

Editorial: Diagnosis, treatment and prognosis of neuroendocrine neoplasms with a focus on peptide receptor radionuclide therapy (PRRT). [PDF]

Front Endocrinol (Lausanne)
Spyroglou A, Holmager P, Alexandraki KI.
europepmc   +1 more source

Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors

With the advent of peptide receptor radionuclide therapy, the timing and sequence of surgery in the treatment of metastatic gastroenteropancreatic neuroendocrine tumors merits further study.
Tobias, Joseph, Gujarathi, Rushabh, Nordgren, Rachel, Millis, J. Michael, Keutgen, Xavier M., Feinberg, Nicholas, Liao, Chih-Yi, Vaghaiwalla, Tanaz, Abou Azar, Sara   +8 more
core   +1 more source

Efficacy of peptide receptor radionuclide therapy in patients with oligodiscordant gastroenteropancreatic neuroendocrine tumours. [PDF]

Eur J Nucl Med Mol Imaging
Mok C, Chow W, Sabahi Z, Bernard EJ, Roach PJ, Bailey DL, Diakos CI, Pavlakis N, Chan DL.   +8 more
europepmc   +1 more source

Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy. [PDF]

Arch Endocrinol Metab
Silva BTD, Maia A, Pereira MT, Santos S, Garrido S, Vilaverde J, Moreira MS, Pinto C, Santos AP, Dores J.   +9 more
europepmc   +1 more source

Optimization of Gravity Infusion Protocols for ¹⁷⁷Lu-DOTATATE Administration in Peptide Receptor Radionuclide Therapy. [PDF]

Pharmaceutics
Grasso S, Varallo A, Gaudieri V, Klain M, Pastore R, Arena S, Oliviero C, Buono M, Manzi D, Schiano R, Nappi C, Totaro P, Bonifacio RR, Cuocolo A, Clemente S.   +14 more
europepmc   +1 more source

Immunogenic cell death as a mechanism of synergy between sunitinib and ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors. [PDF]

Cell Death Discov
Essler M, Veit N, Müller A, Marinova M, Kreppel B.   +4 more
europepmc   +1 more source

Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors. [PDF]

JCO Precis Oncol
Bogdani C, Karimi A, Li R, Atkinson EC, Oberstein PE, Siolas D.   +5 more
europepmc   +1 more source